ADMA Biologics Inc. ADMA shares are moving higher after it was announced that the company will join the S&P SmallCap 600.
The Details: ADMA Biologics will replace Olympic Steel Inc. ZEUS in the S&P SmallCap 600.
This change will take effect before the market opens on September 23. Other companies in the healthcare sector are also joining the index, including TG Therapeutics TGTX.
How To Buy ADMA Biologics Shares
By now you're likely curious about how to participate in the market for ADMA Biologics ADMA – be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
In the the case of ADMA Biologics ADMA, which is trading at $18.84 as of publishing time, $100 would buy you 5.31 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.
Related Link: Nasdaq Surges Over 1%; US Wholesale Inventories Rise 0.2% In July
AMDA Price Action: At the time of writing, ADMA Biologics stock is moving 13.3% higher at $18.43, according to data from Benzinga Pro.
Image: Unsplash/ Volodymyr Hryshchenko
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.